| Manorcare Health Services | |
| 13881 Eagle Ridge Drive, Fort Myers, Florida 33912 | |
| (239) 561-7700 | |
| Name | Manorcare Health Services |
|---|---|
| Location | 13881 Eagle Ridge Drive, Fort Myers, Florida |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 120 |
| Occupancy Rate | 79.75% |
| Medicare ID (CCN) | 106020 |
| Legal Business Name | Manor Care Of Ft Myers Fl Llc |
| Ownership Type | Non Profit - Corporation |
| NPI Number | 1184671737 |
| Organization Name | MANOR CARE OF FT MYERS FL LLC |
| Doing Business As | MANORCARE HEALTH SERVICES |
| Address | 13881 Eagle Ridge Dr, Ft Myers, FL 33912 |
| Phone Number | 239-561-7700 |
News Archive
REPLICor Inc., a privately owned biopharmaceutical company, is developing a broad spectrum antiviral drug called REP 9 which has the broadest spectrum of activity in vitro ever reported for a single chemical entity.
The Global Alliance for TB Drug Development and AstraZeneca announced today at the 2010 BIO International Convention that they have entered into a research collaboration agreement to accelerate the discovery, development and clinical use of drugs against tuberculosis, including drug resistant strains of the disease.
The Asynt GP540 is a new bench-mounted, general-purpose, ventilated laboratory cabinet designed for use in a wide-range of applications.
The Alliance for the Prudent Use of Antibiotics (APUA) has announced a $1.37 million grant from the Bill & Melinda Gates Foundation, to explore ways of reducing millions of preventable deaths from severe respiratory and diarrheal infections in Africa. This project was announced in conjunction with a colloquium at the annual ICAAC/IDSA meeting warning of increasing antibiotic resistance.
› Verified 8 days ago
| NPI Number | 1700591138 |
| Organization Name | EAGLERIDGE OPERATIONS, LLC |
| Address | 13881 Eagle Ridge Dr, Fort Myers, FL 33912 |
| Phone Number | 239-561-7700 |
News Archive
REPLICor Inc., a privately owned biopharmaceutical company, is developing a broad spectrum antiviral drug called REP 9 which has the broadest spectrum of activity in vitro ever reported for a single chemical entity.
The Global Alliance for TB Drug Development and AstraZeneca announced today at the 2010 BIO International Convention that they have entered into a research collaboration agreement to accelerate the discovery, development and clinical use of drugs against tuberculosis, including drug resistant strains of the disease.
The Asynt GP540 is a new bench-mounted, general-purpose, ventilated laboratory cabinet designed for use in a wide-range of applications.
The Alliance for the Prudent Use of Antibiotics (APUA) has announced a $1.37 million grant from the Bill & Melinda Gates Foundation, to explore ways of reducing millions of preventable deaths from severe respiratory and diarrheal infections in Africa. This project was announced in conjunction with a colloquium at the annual ICAAC/IDSA meeting warning of increasing antibiotic resistance.
› Verified 8 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
REPLICor Inc., a privately owned biopharmaceutical company, is developing a broad spectrum antiviral drug called REP 9 which has the broadest spectrum of activity in vitro ever reported for a single chemical entity.
The Global Alliance for TB Drug Development and AstraZeneca announced today at the 2010 BIO International Convention that they have entered into a research collaboration agreement to accelerate the discovery, development and clinical use of drugs against tuberculosis, including drug resistant strains of the disease.
The Asynt GP540 is a new bench-mounted, general-purpose, ventilated laboratory cabinet designed for use in a wide-range of applications.
The Alliance for the Prudent Use of Antibiotics (APUA) has announced a $1.37 million grant from the Bill & Melinda Gates Foundation, to explore ways of reducing millions of preventable deaths from severe respiratory and diarrheal infections in Africa. This project was announced in conjunction with a colloquium at the annual ICAAC/IDSA meeting warning of increasing antibiotic resistance.
› Verified 8 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 4 |
| Total Amount of Fines in Dollars | $344031 |
| Number of Payment Denials | 1 |
| Total Number of Penalties | 5 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 9.28 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 6.67 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 55.34 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 0.78 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 1.28 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 1.12 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 98.88 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 18.35 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 91.36 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 2.96 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 27.11 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 13.45 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 7.08 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 92.79 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 76.59 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 78.64 | 82.93 |
News Archive
REPLICor Inc., a privately owned biopharmaceutical company, is developing a broad spectrum antiviral drug called REP 9 which has the broadest spectrum of activity in vitro ever reported for a single chemical entity.
The Global Alliance for TB Drug Development and AstraZeneca announced today at the 2010 BIO International Convention that they have entered into a research collaboration agreement to accelerate the discovery, development and clinical use of drugs against tuberculosis, including drug resistant strains of the disease.
The Asynt GP540 is a new bench-mounted, general-purpose, ventilated laboratory cabinet designed for use in a wide-range of applications.
The Alliance for the Prudent Use of Antibiotics (APUA) has announced a $1.37 million grant from the Bill & Melinda Gates Foundation, to explore ways of reducing millions of preventable deaths from severe respiratory and diarrheal infections in Africa. This project was announced in conjunction with a colloquium at the annual ICAAC/IDSA meeting warning of increasing antibiotic resistance.
› Verified 8 days ago
Heritage Park Rehabilitation And Healthcare Location: 2826 Cleveland Ave, Fort Myers, Florida 33901 Phone: (239) 334-1091 | |
Signature Healthcare At College Park Location: 13755 Golf Club Pkwy, Fort Myers, Florida 33919 Phone: (239) 482-2848 | |
Fort Myers Rehabilitation And Nursing Center Location: 7173 Cypress Drive Sw, Fort Myers, Florida 33907 Phone: (239) 936-0203 | |
Consulate Health Care Of North Fort Myers Location: 991 Pondella Rd, Fort Myers, Florida 33903 Phone: (239) 995-8809 | |
Heartland Health Care Center Fort Myers Location: 1600 Matthew Drive, Fort Myers, Florida 33907 Phone: (239) 275-6067 |